HKD 5.05
(0.2%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 192.27 Million CNY | -11.32% |
2022 | 655.6 Million CNY | -30.56% |
2021 | 944.08 Million CNY | 110.11% |
2020 | 449.32 Million CNY | 7.21% |
2019 | 419.1 Million CNY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 160.55 Million HKD | -39.93% |
2024 Q2 | 159.17 Million HKD | -0.15% |
2023 Q3 | -39.42 Million HKD | -114.94% |
2023 FY | 581.4 Million CNY | -11.32% |
2023 Q4 | 272.61 Million HKD | 791.49% |
2023 Q2 | 263.81 Million HKD | 73.67% |
2023 Q1 | 151.9 Million HKD | -54.65% |
2022 FY | 655.6 Million CNY | -30.56% |
2022 Q2 | 285.83 Million HKD | 0.0% |
2022 Q4 | 334.95 Million HKD | 0.0% |
2021 FY | 944.08 Million CNY | 110.11% |
2021 Q2 | 504.58 Million HKD | 0.0% |
2020 FY | 449.32 Million CNY | 7.21% |
2019 FY | 419.1 Million CNY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Uni-Bio Science Group Limited | 325.05 Million HKD | 40.846% |
CK Life Sciences Int'l., (Holdings) Inc. | 739.25 Million HKD | 73.99% |